（记者 曾健辉） 每经头条（nbdtoutiao）——地方国资开始"抄底"法拍房！单价六七千元"扫货"广州南沙区超60套房 源，同小区二手房挂牌均价逾2万元 每经AI快讯，灵康药业1月23日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 为-1.27亿元左右，与上年同期相比，减亏2.88%左右。2025年度亏损的主要原因为销售毛利无法覆盖期 间费用，导致经营业绩亏损。报告期内，随着药品集采政策持续推进，行业市场竞争加剧，公司努力将 产品市场覆盖率与产品价格形成最佳合理机制，由于抗感染类部分产品处于集采新旧标期过渡阶段、中 标品种价格下降等因素导致该大类销售收入较上年同期下降70%左右；由于国内心脑血管类产品逐渐获 批上市，市场需求的扩大与产品日渐增多形成竞争效应，导致该大类收入下降30%左右；产能利用率偏 低，导致单位产品分摊的折旧、人工等固定成本相对较高，闲置产能停工损失直接计入成本对整体利润 形成较大压力；公司充分利用销售体系的优势，进一步拓展医药代理及流通业务，以做大做强公司规 模，该业务收入较上年同期大幅增长。 ...

南财智讯1月23日电，灵康药业发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-12,700万元左右，同比减亏约2.88%；预计2025年全年归属于上市公司股东的扣除非经常性损益的净 利润为-14,700万元左右，同比减亏约18.41%；2025年度亏损的主要原因为销售毛利无法覆盖期间费 用，导致经营业绩亏损。报告期内，随着药品集采政策持续推进，行业市场竞争加剧，公司努力将产品 市场覆盖率与产品价格形成最佳合理机制，由于抗感染类部分产品处于集采新旧标期过渡阶段、中标品 种价格下降等因素导致该大类销售收入较上年同期下降70%左右；由于国内心脑血管类产品逐渐获批上 市，市场需求的扩大与产品日渐增多形成竞争效应，导致该大类收入下降30%左右；产能利用率偏低， 导致单位产品分摊的折旧、人工等固定成本相对较高，闲置产能停工损失直接计入成本对整体利润形成 较大压力；公司充分利用销售体系的优势，进一步拓展医药代理及流通业务，以做大做强公司规模，该 业务收入较上年同期大幅增长。 ...

Group 1 - The company announced a management change with the resignation of CFO Zhou Yana due to personal reasons, and General Manager Cai Yonggang will temporarily assume CFO responsibilities until a new appointment is made [2] - The board expressed gratitude for Zhou Yana's contributions and emphasized that the management change is a normal adjustment that will not impact the company's operations or financial management [2] Group 2 - Northeast Pharmaceutical is a large comprehensive pharmaceutical enterprise in China, with a diverse product matrix covering chemical raw materials and formulations, including core products like Vitamin C, anti-infection products, neurological drugs, and anti-tumor medications [3] - The company is actively optimizing its strategy by increasing investment in innovative drugs and high-value generics while expanding into international markets to maintain a stable market position [3] Group 3 - The company's financial performance in the first half of 2025 showed a decline in both revenue and net profit, with revenue at 3.853 billion yuan, down 7.58% year-on-year, and net profit at 129 million yuan, down 17.62% [4] - R&D expenses significantly increased to 83.49 million yuan, a rise of 84.09% compared to the previous year, indicating a strong commitment to innovation [4] Group 4 - The company has experienced frequent changes in key management positions over the past three years, including roles such as director, board secretary, and vice president [5] - The reasons for these changes are attributed to the need for strategic optimization and industry environment shifts, with plans to enhance the management team through a combination of internal selection and external recruitment [6]

Group 1 - The core point of the article is that Hendi Pharmaceutical plans to increase its share capital by issuing 4.5 additional shares for every 10 shares held by shareholders, without arranging for cash dividends [1] - As of August 19, 2025, Hendi Pharmaceutical's stock price is 18.80 yuan, reflecting a 0.43% increase from the previous trading day, with a trading volume of 113 million yuan [1] - For the first half of 2025, the company reported revenue of 235 million yuan and a net profit attributable to shareholders of 18.55 million yuan [1] Group 2 - Hendi Pharmaceutical operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of APIs and formulations, with products in the fields of antipyretic analgesics and anti-infectives [1] - On the same day, the net inflow of main funds was 9.0143 million yuan, accounting for 0.17% of the circulating market value, while the net outflow over the past five days was 15.5961 million yuan, representing 0.29% of the circulating market value [1]

Group 1 - As of August 7, 2025, the stock price of Peking University Pharmaceutical is 6.81 yuan, down 1.02% from the previous trading day, with a trading volume of 146 million yuan and a turnover rate of 3.58% [1] - Peking University Pharmaceutical operates in the chemical pharmaceutical industry, with main business areas including pharmaceutical manufacturing, pharmaceutical distribution, and medical services. The company's products cover multiple therapeutic areas such as anti-infection, cardiovascular, and digestive systems [1] - As of July 31, 2025, the total number of shareholders is 53,400, an increase of 10.77% from the previous period. The average number of shares held per shareholder has decreased to 11,200 shares, with an average market value of 77,100 yuan, which is below the average level of the pharmaceutical and biotechnology industry [1] Group 2 - On August 7, 2025, the net outflow of main funds is 12.88 million yuan, with a cumulative net outflow of 50.01 million yuan over the past five days [1]

Group 1 - The core viewpoint of the news is that Taiji Group (600129.SH) announced a share repurchase plan to boost market confidence amid significant performance declines [1][2] - The company plans to repurchase shares worth between 80 million yuan and 120 million yuan, with a maximum repurchase price of 28.03 yuan per share, and the repurchase period is set for 12 months from the approval date [1][2] - The estimated number of shares to be repurchased ranges from approximately 285,410 to 428,110 shares, accounting for about 0.51% to 0.77% of the company's total share capital [1] Group 2 - Taiji Group's stock price has decreased approximately 68% from its peak of 68.14 yuan per share on May 31, 2023, to 21.76 yuan per share as of July 16, 2023 [2] - The company reported a 20.72% year-on-year decline in revenue for 2024, totaling 12.386 billion yuan, and a drastic 96.76% drop in net profit attributable to shareholders, amounting to 26.6527 million yuan [2] - For the first half of 2025, the company anticipates a net profit of approximately 139 million yuan, reflecting a year-on-year decline of about 71.9% [2] Group 3 - Despite the pressure on performance and costs, the company continues to invest in research and development, focusing on product re-development and new product innovation [3] - Taiji Group is also enhancing its marketing reform and operational control while strictly managing shipments to improve sales performance [3] - The company expects non-recurring gains and losses to impact net profit attributable to shareholders by approximately 19 million yuan, a decrease of about 5.5 million yuan compared to the previous year [3]